|
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of protriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Protriptyline hydrochloride is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use)
|
VIVACTIL NEWS HIGHLIGHTS Media Articles Related to Vivactil (Protriptyline)
Depression linked to poorer diabetes control (Reuters) Source: Y! Health Depression News [2008.11.19]
Depression Screening May Not Benefit Heart Disease Patients Source: Depression News From Medical News Today [2008.11.17]
AMPAKINE(R) Compounds May Protect From Drug-induced Respiratory Depression While Still Allowing The Sedative Or Analgesic To Continue Working Source: Respiratory / Asthma News From Medical News Today [2008.11.16]
Greater Risk Of Death For African-Americans With Depression And Heart Attack Source: Depression News From Medical News Today [2008.11.13]
Heart Association Call For Routine Screening Of Heart Patients For Depression Is Premature, Johns Hopkins Expert Says Source: Depression News From Medical News Today [2008.11.12]
Published Studies Related to Vivactil (Protriptyline)
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
Protriptyline, chronic tension-type headaches, and weight loss in women. [1997.07]
Clinical Trials Related to Vivactil (Protriptyline)
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
|